Patents by Inventor Matthew Volgraf

Matthew Volgraf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS
    Publication number: 20250122184
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: December 18, 2024
    Publication date: April 17, 2025
    Applicant: Genentech, Inc.
    Inventors: Jack Alexander TERRETT, Huifen CHEN, Lea CONSTANTINEAU-FORGET, Robin Larouche-Gauthier, Luce LÉPISSIER, Francis BEAUMIER, Martin DÉRY, Chantal GRAND-MAÎTRE, Claudio STURINO, Matthew VOLGRAF, Elisia VILLEMURE
  • SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
    Publication number: 20250115618
    Abstract: The present disclosure relates to novel sulfonimidamide compounds and related compounds and their use in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Application
    Filed: December 19, 2024
    Publication date: April 10, 2025
    Applicant: Genentech, Inc.
    Inventors: Christopher MCBRIDE, Lynnie Lin TRZOSS, Amogh BOLOOR, Nadezda V. SOKOLOVA, Richard M. PASTOR, Steven Thomas STABEN, Craig STIVALA, Matthew VOLGRAF, Sarah M. BRONNER
  • Sulfonimidamide compounds as inhibitors of interleukin-1 activity
    Patent number: 12234245
    Abstract: The present disclosure relates to novel sulfonimidamide compounds and related compounds and their use in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: February 25, 2025
    Assignee: Genentech, Inc.
    Inventors: Christopher McBride, Lynnie Lin Trzoss, Amogh Boloor, Nadezda V. Sokolova, Richard M. Pastor, Steven Thomas Staben, Craig Stivala, Matthew Volgraf, Sarah M. Bronner
  • Oxadiazole transient receptor potential channel inhibitors
    Patent number: 12202824
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: August 2, 2022
    Date of Patent: January 21, 2025
    Assignee: Genentech, Inc.
    Inventors: Jack Alexander Terrett, Huifen Chen, Lea Constantineau-Forget, Robin Larouche-Gauthier, Luce Lépissier, Francis Beaumier, Martin Déry, Chantal Grand-Maître, Claudio Sturino, Matthew Volgraf, Elisia Villemure
  • SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
    Publication number: 20240398781
    Abstract: The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.
    Type: Application
    Filed: May 21, 2024
    Publication date: December 5, 2024
    Inventors: Marie-Gabrielle BRAUN, Georgette CASTANEDO, William VERNIER, Matthew VOLGRAF, James Guy BREITENBUCHER, Brad LANG
  • SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
    Publication number: 20240400579
    Abstract: The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of myelin-related disorders.
    Type: Application
    Filed: May 21, 2024
    Publication date: December 5, 2024
    Inventors: William VERNIER, Matthew VOLGRAF, Marie-Gabrielle BRAUN, Georgette Marie CASTANEDO, Paul Anthony GIBBONS, James Guy BREITENBUCHER, Drew ADAMS, Brad LANG
  • SPIROCYCLIC BICYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
    Publication number: 20240391930
    Abstract: The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.
    Type: Application
    Filed: May 21, 2024
    Publication date: November 28, 2024
    Inventors: Marie-Gabrielle BRAUN, Georgette CASTANEDO, William VERNIER, Matthew VOLGRAF, Michael SIU, James Guy BREITENBUCHER
  • SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME
    Publication number: 20240228463
    Abstract: The invention provides compounds of formulae I, II, IIa, and III: and pharmaceutically acceptable salts thereof, as well as compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: February 22, 2024
    Publication date: July 11, 2024
    Applicant: Genentech, Inc.
    Inventors: Marc KSCHONSAK, Steven John MCKERRALL, Daniel Fred ORTWINE, Jian Mehr-Dean PAYANDEH, Benjamin Douglas SELLERS, John C. TELLIS, Matthew VOLGRAF, Philippe BERGERON, Claudio CIFERRI, Peter Scott DRAGOVICH
  • Oxadiazole transient receptor potential channel inhibitors
    Patent number: 11655245
    Abstract: The invention relates to methods of using compounds formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: May 23, 2023
    Assignee: Genentech, Inc.
    Inventors: Jack Alexander Terrett, Huifen Chen, Lea Constantineau-Forget, Robin Larouche-Gauthier, Luce Lépissier, Francis Beaumier, Martin Déry, Chantal Grand-Maître, Claudio Sturino, Matthew Volgraf, Elisia Villemure
  • OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS
    Publication number: 20230121700
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: August 2, 2022
    Publication date: April 20, 2023
    Applicant: Genentech, Inc.
    Inventors: Jack Alexander TERRETT, Huifen CHEN, Lea CONSTANTINEAU-FORGET, Robin Larouche-Gauthier, Luce LÉPISSIER, Francis BEAUMIER, Martin DÉRY, Chantal GRAND-MAÎTRE, Claudio STURINO, Matthew VOLGRAF, Elisia VILLEMURE
  • Sulfonylurea compounds as inhibitors of interleukin-1 activity
    Patent number: 11560391
    Abstract: The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: January 24, 2023
    Assignee: Genentech, Inc.
    Inventors: Jeffrey A. Stafford, James M. Veal, Lynnie Lin Trzoss, Christopher McBride, Richard M. Pastor, Steven Thomas Staben, Craig Stivala, Matthew Volgraf
  • SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
    Publication number: 20210261568
    Abstract: The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Application
    Filed: January 15, 2021
    Publication date: August 26, 2021
    Applicant: Genentech, Inc.
    Inventors: Jeffrey A. STAFFORD, James M. VEAL, Lynnie Lin TRZOSS, Christopher MCBRIDE, Richard M. PASTOR, Steven Thomas STABEN, Craig STIVALA, Matthew VOLGRAF
  • SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
    Publication number: 20210253596
    Abstract: The present disclosure relates to novel sulfonimidamide compounds and related compounds and their use in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Application
    Filed: January 15, 2021
    Publication date: August 19, 2021
    Applicant: Genentech, Inc.
    Inventors: Christopher MCBRIDE, Lynnie Lin TRZOSS, Amogh BOLOOR, Nadezda V. SOKOLOVA, Richard M. PASTOR, Steven Thomas STABEN, Craig STIVALA, Matthew VOLGRAF, Sarah M. BRONNER
  • Oxadiazolones as transient receptor potential channel inhibitors
    Patent number: 10913742
    Abstract: The invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as respiratory disorders or pain.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: February 9, 2021
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Daniel Shore, Elisia Villemure, Matthew Volgraf, Baihua Hu, Aijun Lu, Andrew Cridland, Stuart Ward, Francis Beaumier, Martin Dery, Robin Larouche-Gauthier
  • OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS
    Publication number: 20200308161
    Abstract: The invention relates to methods of using compounds formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Applicant: Genentech, Inc.
    Inventors: Jack Alexander Terrett, Huifen Chen, Lea Constantineau-Forget, Robin Larouche-Gauthier, Luce Lépissier, Francis Beaumier, Martin Déry, Chantal Grand-Maître, Claudio Sturino, Matthew Volgraf, Elisia Villemure
  • Sulfonylcycloalkyl carboxamide compounds
    Patent number: 10766878
    Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: September 8, 2020
    Assignee: Genentech, Inc.
    Inventors: Baihua Hu, Vishal Verma, Matthew Volgraf, Anthony Estrada, Joseph Lyssikatos
  • Oxadiazole transient receptor potential channel inhibitors
    Patent number: 10710994
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: July 14, 2020
    Assignee: Genentech, Inc.
    Inventors: Jack Alexander Terrett, Huifen Chen, Lea Constantineau-Forget, Robin Larouche-Gauthier, Luce Lépissier, Francis Beaumier, Martin Déry, Chantal Grand-Maître, Claudio Sturino, Matthew Volgraf, Elisia Villemure
  • Oxadiazole transient receptor potential channel inhibitors
    Patent number: 10711004
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: July 14, 2020
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Brian Safina, Daniel Shore, Jack Terrett, Elisia Villemure, Matthew Volgraf, Stuart Ward, Aijun Lu, Robin Larouche-Gauthier, Francis Beaumier, Martin Dery, Lea Constantineau-Forget, Chantal Grand-Maitre, Luce Lepissier
  • Sulfonyl pyridyl TRP inhibitors
    Patent number: 10695348
    Abstract: The invention provides compounds of formula I: and pharmaceutically acceptable salts thereof where R1 is a substituted or unsubstituted phenyl or a fused bicyclic comprising a substituted or unsubstituted phenyl. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: June 30, 2020
    Assignee: Genentech, Inc.
    Inventors: Vishal Verma, Matthew Volgraf, Baihua Hu
  • Thiazolopyrimidinones and methods of use thereof
    Patent number: 10647731
    Abstract: The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: May 12, 2020
    Assignee: Genentech, Inc.
    Inventors: Yu Jiang, Guosheng Wu, Po-Wai Yuen, Elisia Villemure, Jacob Schwarz, Cuong Ly, Benjamin Sellers, Matthew Volgraf